semaglutide plateau after 1 month Weight maintenance discontinuation of GLP-1 therapies How Long Do You Stay

TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus

(2018) 102:e166e75

JAMA , 325(14), 14141425.

These ongoing trials represent important steps toward clarifying the role of GLP-1 RAs as disease-modifying agents in PD and may pave the way for more targeted and effective therapies

Future investigation should also clarify whether the benefit is driven by direct antitumor effects of GLP-1 RAs or by indirect mechanisms mediated through weight loss and cardiometabolic risk reduction

This risk is higher if you have existing chronic kidney disease or take certain medications like ACE inhibitors or diuretics